EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study

Leilei Wu iD, Bo Cheng, Xiaojiang Sun, Zhenshan Zhang iD, Jingjing Kang, Yun Chen, Qinghua Xu, Shuangyan Yang, Yujie Yan, Shengxiang Ren, Caicun Zhou, Yaping Xu iD

MedComm · 2024-03 · 5 (3)

DOI: 10.1002/mco2.501 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift MedComm, online erschienen am 02.03.2024. Verfasst von Leilei Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology Shanghai Pulmonary Hospital School of Medicine Tongji University Shanghai China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the efficacy and safety of induction immunochemotherapy followed by definitive chemoradiotherapy (CRT) for unresectable locally advanced non‐small cell lung cancer (LA‐NSCLC). We identified unresectable stage III NSCLC patients who received induction immunochemotherapy. Overall survival (OS) and progression‐free survival (PFS) were the primary endpoints. From February 2019 to August 2022, 158 patients were enrolled. Following the completion of induction immunochemotherapy, the objective response rate (ORR) and disease control rate (DCR) were 52.5% and 83.5%, respectively. The ORR of CRT was 73.5%, representing 68.4% of the total cohort. The median PFS was 17.8 months, and the median OS was 41.9 months, significantly higher than in patients who received CRT alone ( p < 0.001). Patients with concurrent CRT demonstrated markedly improved PFS ( p = 0.012) and OS ( p = 0.017) than those undergoing sequential CRT. Additionally, those with a programmed‐death ligand 1 (PD‐L1) expression of 50% or higher showed significantly elevated ORRs (72.2% vs. 47.2%, p = 0.011) and superior OS (median 44.8 vs. 28.6 months, p = 0.004) compared to patients with PD‐L1 expression below 50%. Hematologic toxicities were the primary severe adverse events (grade ≥ 3) encountered, with no unforeseen treatment‐related toxicities. Thus, induction immunochemotherapy followed by definitive CRT demonstrated encouraging efficacy and tolerable toxicities for unresectable LA‐NSCLC.

Schlagwörter

Stichwörter der Autor:innen

Induction immunochemotherapydefinitive chemoradiotherapysurvivalunresectable LA‐NSCLC

Autor:innen und Institutionen

  • Department of Radiation Oncology Shanghai Pulmonary Hospital School of Medicine Tongji University Shanghai China.
  • Department of Radiation Oncology Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Cancer and Basic Medicine (IBMC) Chinese Academy of Sciences Hangzhou China.
  • Department of Radiation Oncology Qilu Hospital Cheeloo College of Medicine Shandong University Jinan China.
  • Department of Radiation Oncology Shanghai Proton and Heavy Ion Center Fudan University Cancer Hospital Shanghai China.
  • Department of Medical Oncology Shanghai Pulmonary Hospital School of Medicine Tongji University Shanghai China.

ORCID-Profile: Leilei Wu, Zhenshan Zhang, Yaping Xu

Zitieren

APA

Wu, L., Cheng, B., Sun, X., Zhang, Z., Kang, J., Chen, Y., Xu, Q., Yang, S., Yan, Y., Ren, S., Zhou, C., & Xu, Y. (2024). Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study. MedComm, 5(3). https://doi.org/10.1002/mco2.501

Vancouver

Wu L, Cheng B, Sun X, Zhang Z, Kang J, Chen Y, et al. Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study. MedComm. 2024;5(3). doi:10.1002/mco2.501

BibTeX
@article{Wu2024,
  author = {Wu, Leilei and Cheng, Bo and Sun, Xiaojiang and Zhang, Zhenshan and Kang, Jingjing and Chen, Yun and Xu, Qinghua and Yang, Shuangyan and Yan, Yujie and Ren, Shengxiang and Zhou, Caicun and Xu, Yaping},
  title = {Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {3},
  doi = {10.1002/mco2.501}
}
Kostenlos starten →